$NTRA

Rabinowitz Matthew sold $196K of NTRA

Rabinowitz Matthew (EXECUTIVE CHAIRMAN) sold 731 shares of Natera, Inc. (NTRA) at $267.99 ($0.20M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Rabinowitz Matthew
Published Aug 6, 2026, 1:35 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale of 731 shares at $267.9893 on 2026-08-03, with the filing made on 2026-08-05, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 designation generally limits actionable signal for valuation or near-term catalysts.

03

What to watch

The article provides only the sale details and post-transaction holdings; it does not include any concurrent buy activity, guidance changes, or operational updates.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05 for a sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA) by executive chairman Matthew Rabinowitz.

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera executive chairman Matthew Rabinowitz sold 731 shares in an open-market transaction for about $195.9K, disclosed via Form 4.

Expected impact

Likely minimal impact on NTRA price; any effect would be short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a routine Form 4 insider transaction and explicitly notes a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No clear sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, some traders may view insider selling as a mild negative sentiment input, especially if paired with other negative signals not present here.

Key entities

  • Natera, Inc.

    Company whose executive chairman insider sale is disclosed on Form 4.

  • Matthew Rabinowitz

    Executive chairman and reporting person who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either.

Billionaire investor Stanley Druckenmiller's largest Q2 holding was Natera (NTRA), a genetic testing company, not Amazon or Alphabet. Natera reported Q2 2026 revenue of $752.8M, up 39% YoY, and raised full-year guidance to $2.85B-$2.91B. The company's Signatera cancer detection test is a key growth driver, with FDA, PMDA, and EU approvals.

$NTRAMedAI 8/10

Natera (NTRA) Q2 2026 Earnings Call Transcript

Natera (NTRA) reported Q2 2026 revenue of $752.8 million, up 37.7% year over year, and net loss per diluted share of ($0.47), improved from ($0.74). Total tests processed rose 22.4% to 1,043,900. The company raised full-year revenue guidance to $2.85 billion to $2.91 billion and cited FDA and PMDA approvals for Signatera.

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.